MDD logo ACS Publications
July 2004 From Concept to Development
About MDD
Volume 7, Issue 7
Article Indexes
Author Indexes


Good things in small packagesGood things in small packages
by Randall C. Willis

PDF version (440 KB PDF)
For all of the technical advances that have been made that allow researchers to identify greater numbers of lead compounds and screen wider arrays of cell types, pharmaceutical specialists are still challenged by the prospect of getting the right compound to the right spot in the human body where it can have the maximum effect. Researchers are looking to nanotechnology to provide drug delivery vehicles that carry large therapeutic payloads.

Special Section: Birth of a drugSpecial Section: Birth of a drug
by Aalok Mehta

PDF version (250 KB PDF)
Drug discovery is a remarkably robust field. The pharmaceutical industry continues to weather tough economic times better than most other sectors and continues to pour money into R&D. New treatments are constantly emerging, giving hope to both the terminally stricken and the perpetually pained. And for chemists, drug discovery offers numerous jobs with a very real purpose and a human face, involving them in all aspects of the process, from the inception of the idea to the handoff of a potential chemical candidate to the development organization.

Drug resistance and microarraysDrug resistance and microarrays
by Chung-Hae Lee and Pascale F. Macgregor

PDF version (120 KB PDF)
In cancer research, great hopes were held that microarrays would break the code of cancer cells, leading to better detection and more accurate diagnosis and prognosis. Visions blossomed of personalized medicine, better response rates, decreased side effects and drug resistance, and, eventually, higher cancer cure rates. But thousands of microarray papers later, what have we learned, and where are the success stories?


Ready to Read (60 KB PDF)
Building Global Biobrands
Reviewed by Randall C. Willis
[Buy from]

Product Info Now (html)

On the Calendar
BioMEMS and Biodefense
(60 KB PDF)
Cancer and pathogen detection take center stage in the nation’s capital.

Content in Context
Seeking future growth (32 KB PDF)
by Ann M. Thayer

New and Noteworthy (120 KB PDF)
Cancer vaccine collaboration • Stem cell savings • Fixing defective genes • Hepatitis C handoffs • Bugs to drugs • Pushing NMR sensitivity • Spotting the difference • Novel angina treatment

Focus on Business

Marketplace, deals, and people (56 KB PDF)

When the "reach-through" exceeds the grasp (76 KB PDF)
by Phillip B. C. Jones
Court rulings on a COX-2 inhibitor patent lead others to consider alternatives for protecting early-stage technology.

Imbalanced innovation: European "free ride" in R&D has its limit (88 KB PDF)
by Kimberly S. Cleaves
The European pharmaceutical industry faces a dilemma in controlling R&D costs.

People and Perspectives

Glass houses (64 KB PDF)
by Randall C. Willis
While regulators slow progress, pharma can also find fault within.

Microwaves lend a hand (60 KB PDF)
by Michael J. Collins
Researchers offer examples of microwave-assisted synthesis taking hold in everyday lab practices.

Diseases and Disorders
(80 KB PDF)
by Evelyn B. Kelly
Biotech is bringing forth new products against an ancient disease.

Rules and Regulators
Clearing the critical path
(64 KB PDF)
by David Filmore
The FDA is advancing a new initiative to bring 21st-century tools to medical product development.

Clinical Trials Track
A new drug for lupus?
(104 KB PDF)
by David Filmore
Like the disease it targets, the case for Riquent is not clear-cut.

Applications Notebook
Neural cell differentiation
(76 KB PDF)
by Paul Wylie
High-content screening confronts the challenges for high-throughput and secondary assays.

Sites and Software
Can't (under)stand the heat? (96 KB PDF)
by Robert Royce
As genomic assays become more complex, hybridization software becomes hotter.

The Tool Box
Unfolding the potential of proteins
(68 KB PDF)
by Joby Marie Chesnick
New refolding technologies are essential for making useful recombinant proteins.